A Study on the Significance of Combining Kampo Medicine with the Molecular Targeted Drug Lenvatinib for Unresectable Thyroid Cancer and Related Drug Interactions

A Study on the Significance of Combining Kampo Medicine with the Molecular Targeted Drug Lenvatinib for Unresectable Thyroid Cancer and Related Drug Interactions - A Study on the Significance of Combining Kampo Medicine with the Molecular Targeted Drug Lenvatinib for Unresectable Thyroid Cancer and Related Drug Interactions

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000060733

Enrollment

Registered

2026-02-28

Start date

2023-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer

Interventions

Combined use of Kampo medicine No concomitant use of Kampo medicine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with unresectable advanced thyroid cancer who initiated lenvatinib therapy at Ito Hospital between May 1, 2015, and December 31, 2019

Exclusion criteria

Exclusion criteria: Consent for this study could not be obtained

Design outcomes

Primary

Measure	Time frame
Overall survival as of April 30, 2020	—

Secondary

Measure	Time frame
Progression-free survival rate, response rate, dose intensity of lenvatinib and blood concentration of lenvatinib as of April 30, 2020	—

Countries

Japan

Contacts

Public ContactAkifumi Suzuki

Ito Hospital Department of surgery

af-suzuki@ito-hospital.jp03-3402-7411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026